MX2022014943A - Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. - Google Patents

Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.

Info

Publication number
MX2022014943A
MX2022014943A MX2022014943A MX2022014943A MX2022014943A MX 2022014943 A MX2022014943 A MX 2022014943A MX 2022014943 A MX2022014943 A MX 2022014943A MX 2022014943 A MX2022014943 A MX 2022014943A MX 2022014943 A MX2022014943 A MX 2022014943A
Authority
MX
Mexico
Prior art keywords
cov
sars
epitopes
inventors
polypeptides
Prior art date
Application number
MX2022014943A
Other languages
English (en)
Inventor
Yves Levy
Gérard Zurawski
Sandra Zurawski
Christine Lacabaratz
Sylvain Cardinaud
Mathieu Surenaud
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2022014943A publication Critical patent/MX2022014943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)

Abstract

La pandemia del coronavirus 2 causante del síndrome respiratorio agudo severo (SARS-CoV-2) ha surgido innegablemente como la amenaza para la salud global más grande para la humanidad en este siglo; las vacunas de SARS-CoV-2 serán esenciales para reducir la morbilidad y mortalidad si el virus se establece por sí mismo en la población; los inventores han establecido vacunas candidatas contra el SARS-CoV-2; en particular, los inventores han identificado epítopes específicos que se incluirán en los candidatos de vacuna gracias al análisis in silico de la secuencia de aminoácidos de estas proteínas para mapear los epítopes del MHC-I y-II predichos por el software en línea (NetMHC-4.0 y NetMHCII-2.3) y el software de predicción de la unión al péptido; epítopes de células B fueron mapeados también usando el software en línea (BepiPred-2.0 y Discotope), así como regiones ricas en epítopes cuyas secuencias son homólogas entre los SARS-CoV-2 y-CoV-1; finalmente, los inventores han generado algunos anticuerpos de CD40 específicos que comprenden uno o más polipéptidos de SARS-CoV-2 de la presente invención y que son adecuados para propósitos de vacuna; por lo tanto, la presente invención se refiere a polipéptidos de SARS-CoV-2 y usos de los mismos para propósitos de vacuna.
MX2022014943A 2020-05-26 2021-05-26 Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. MX2022014943A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20305550 2020-05-26
EP20306415 2020-11-20
EP21305092 2021-01-26
EP21305482 2021-04-12
PCT/EP2021/064098 WO2021239838A2 (en) 2020-05-26 2021-05-26 Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes

Publications (1)

Publication Number Publication Date
MX2022014943A true MX2022014943A (es) 2023-03-08

Family

ID=76159441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014943A MX2022014943A (es) 2020-05-26 2021-05-26 Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.

Country Status (9)

Country Link
US (1) US20230212231A1 (es)
EP (1) EP4157343A2 (es)
JP (1) JP2023528017A (es)
KR (1) KR20230042222A (es)
BR (1) BR112022024063A2 (es)
CA (1) CA3184802A1 (es)
CO (1) CO2022018389A2 (es)
MX (1) MX2022014943A (es)
WO (1) WO2021239838A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518410B2 (en) * 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
US20240066114A1 (en) * 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
CN118765283A (zh) * 2021-11-17 2024-10-11 国家健康科学研究所 通用沙贝病毒疫苗
CN114807179B (zh) * 2022-06-01 2022-10-21 广州达博生物制品有限公司 一种新型冠状病毒肺炎疫苗的构建与应用
WO2025023616A1 (ko) * 2023-07-21 2025-01-30 세종대학교산학협력단 항 cd98 단일클론항체 및 이의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
CN100588430C (zh) * 2004-02-20 2010-02-10 复旦大学 基于表位的SARS-Cov基因疫苗及其构建
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
DK2114985T3 (en) 2007-02-02 2015-03-30 Baylor Res Inst Complexes of multivariable antigens and target antibody, a humanized
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
RU2539765C2 (ru) 2008-07-16 2015-01-27 Бейлор Рисёч Инститьют ВИЧ ВАКЦИНА, ОСНОВАННАЯ НА НАПРАВЛЕННОСТИ МАКСИМИЗИРОВАННЫХ Gag И Nef НА ДЕНДРИТНЫЕ КЛЕТКИ
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
JP5986382B2 (ja) 2009-03-10 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング癌ワクチン
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
CN102711824A (zh) * 2009-09-14 2012-10-03 贝勒研究院 针对朗格汉斯细胞的疫苗
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
TWI506035B (zh) 2010-08-13 2015-11-01 Baylor Res Inst 以直接針對抗原呈現細胞之抗體的標靶佐劑為主之新穎疫苗佐劑
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2014085580A1 (en) * 2012-11-28 2014-06-05 Baylor Research Institute Methods and compositions involving a flu vaccine
HRP20181251T1 (hr) 2013-09-06 2018-10-05 Aurigene Discovery Technologies Limited Derivati 1,3,4-oksadiazola i 1,3,4-tiadiazola kao imunomodulatori
CU24362B1 (es) 2013-09-06 2018-10-04 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
US10849972B2 (en) * 2018-11-27 2020-12-01 King Adulaziz University Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus
IT202000009625A1 (it) * 2020-04-30 2021-10-30 Takis S R L Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.

Also Published As

Publication number Publication date
CA3184802A1 (en) 2021-12-02
WO2021239838A3 (en) 2022-03-17
WO2021239838A2 (en) 2021-12-02
JP2023528017A (ja) 2023-07-03
US20230212231A1 (en) 2023-07-06
KR20230042222A (ko) 2023-03-28
EP4157343A2 (en) 2023-04-05
CO2022018389A2 (es) 2023-02-06
BR112022024063A2 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
MX2022014943A (es) Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
WO2020193688A3 (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
EA201790976A1 (ru) Терапевтические вакцины против hpv16
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
EA201791148A1 (ru) Способ определения абсолютных количеств hla-рестриктированных раковых пептидов, образовавшихся в результате естественного процессинга
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
JP2015212284A5 (es)
EA201690299A1 (ru) СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
EA200901060A1 (ru) Новый способ и композиции
BR112014030797A2 (pt) epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
MX2022013963A (es) Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
Khan et al. An integrated in silico based subtractive genomics and reverse vaccinology approach for the identification of novel vaccine candidate and chimeric vaccine against XDR Salmonella typhi H58
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
EP3932418A3 (en) Peptides for use in promoting transport of glucose
MX2024004293A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
Chattopadhyay et al. Development and characterization of monoclonal antibody against non-structural protein-2 of Chikungunya virus and its application
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
Aparicio et al. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
Khan et al. Towards a novel peptide vaccine for Middle East respiratory syndrome coronavirus and its possible use against pandemic COVID-19